NDAINTRAVENOUSPOWDERPriority Review
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XERAVA (eravacycline) is a fluorocycline antibiotic administered intravenously as a powder for reconstitution. It is indicated for complicated intra-abdominal infections caused by susceptible gram-negative, gram-positive, and anaerobic bacteria. The drug works by inhibiting bacterial protein synthesis, making it effective against multidrug-resistant pathogens.
$0.788MPart D
Peak11.1 years to LOEProduct is in peak commercial phase with modest Medicare utilization; commercial team is established but growth is limited by indication size and hospital-based distribution.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
Started May 2025
35 enrolled
Complicated Intra-abdominal Infections (cIAI)
Eravacycline Combination Therapy for MRAB
Started Jan 2024
20 enrolled
Pulmonary InfectionPneumonia, BacterialAcinetobacter Baumannii
Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women
Started Nov 2012
20 enrolled
Normal Drug Tolerance
Career Relevance
Working on XERAVA offers career exposure to specialty infectious disease commercial models and hospital-based sales strategies. The product's peak lifecycle stage and clinical specialist job demand suggest roles focused on targeted physician engagement and formulary management in surgical specialties.
Worked on XERAVA at RAPHAS? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.